DocGo

DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services and Mobile Health Solutions. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DocGo reports stellar 2022 performance and outlines growth strategies

DocGo's strong financial performance in 2022, coupled with robust guidance for 2023 and strategic operational initiatives, positions the company for continued growth and profitability.
While challenges like managing PHE impacts and transitioning to leased hour contracts exist, DocGo's proactive approach and operational strengths provide a solid foundation for addressing these hurdles.
With a focus on optimizing operations, pursuing growth opportunities, and leveraging its financial resources effectively, DocGo is poised to capitalize on market opportunities and deliver value to stakeholders.

DocGo reports Q1 revenue growth amidst margin challenges and future opportunities

DocGo's Q1 2023 performance showcased revenue growth and margin challenges, with a focus on improving margins through normalization initiatives.
Strengths include strong revenue guidance, significant contract opportunities, and partnerships driving backlog growth and revenue diversification.
Challenges stem from replacing high-margin COVID revenue, startup costs impacting margins, and negative cash flow in Q1 2023.
Opportunities lie in future revenue growth from new contracts, RPM services, public-private partnerships, and potential contract wins from upcoming RFPs.

DocGo (DCGO) reports stellar Q2 results, raises full-year guidance

DocGo's Q2 2023 showcased exceptional financial performance, with revenue and EBITDA growth exceeding expectations, underpinned by strong operational metrics and strategic decisions.
While facing challenges in backlog conversion and margin improvements, the company's focus on scalability, employee satisfaction, and market expansion positions it well for future growth.
Opportunities in new geographies, Remote Patient Monitoring integration, and transportation segment enhancements provide avenues for sustained revenue growth and operational excellence.

DocGo reports record Q3 revenue, eyes growth in commercial sector

DocGo's Q3 performance reflects strong revenue growth and improved EBITDA margins, driven by the success of Mobile Health and Transportation Services. While facing challenges with working capital and payment delays, the company is focused on catching up by year-end.
The company's strengths in contract performance, revenue guidance increase, and backlog diversification position it well for future growth. DocGo's strategic focus on commercial business expansion and customer experience enhancement aligns with its growth objectives.

DocGo reports record Q4 earnings, eyes growth in healthcare

DocGo delivered exceptional financial results in Q4 2023, showcasing robust revenue growth and profitability, driven by operational excellence and strategic investments.
While facing margin and cost challenges, the company's focus on growth, value-based care agreements, and revenue diversification positions it well for future success and market expansion.
With a strong cash position, revised revenue guidance, and proactive pursuit of new partnerships, DocGo is poised to capitalize on growth opportunities and navigate challenges effectively.
The company's commitment to transforming healthcare delivery and gratitude towards its staff underscore a resilient corporate culture and a dedication to driving positive impact in the industry.

DocGo reports robust Q1 earnings, eyes growth through unique care model

DocGo's Q1 2024 performance was strong, marked by revenue growth, improved margins, and profitability.
While facing challenges like revenue fluctuations and working capital pressures, the company is well-positioned for growth.
Opportunities lie in becoming a primary care provider, monetization strategies, and market differentiation through quality care.
Overall, DocGo's financial stability, growth plans, and unique service offerings position them for future success in the healthcare sector.

DocGo excels in Q2 2024, sets sights on clinical innovation

DocGo's Q2 2024 performance reflects financial strength and strategic advancements in clinical expertise and service expansion.
While facing challenges in meeting ambitious care gap closure targets, the company is well-positioned for growth.
Leveraging opportunities in mobile healthcare services and clinical program development can drive future success for DocGo.

DocGo reports robust Q3 earnings, eyes growth in migrant-related work

DocGo's Q3 2024 earnings call showcased strong financial performance, operational efficiency, and positive outlook for future revenue and cash flow.
While challenges such as revenue balancing and margin expectations were noted, opportunities for growth through migrant-related work and care programs were highlighted.
Overall, DocGo's performance and strategic direction position the company well for continued success and expansion in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services, Mobile Health Solutions, and Corporate. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The Corporate segment consists of information technology expenses. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the second quarter ended June 30, 2024 after the markets close on Wednesday, August 7, 2024. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Wednesday, August 7, 2024 5:00 p.m. ET 1-877-343-4136.

DocGo to Announce Second Quarter 2024 Results on Wednesday, August 7, 2024

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DocGo Inc Is Under Investigation By The Schall Law Firm And Affected Investors Are Encouraged To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating DocGo Inc And Urges Impacted Investors To Initiate Conversations

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DocGo Inc Is Under Examination By The Schall Law Firm, Investors Who Have Been Affected Are Encouraged To Start Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Affected Investors To Initiate Conversation, DocGo Inc Is Under Scrutiny

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DocGo Inc Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Start Dialogue

The Real Brokerage Inc.

MONHEIM AM RHEIN, Germany--(BUSINESS WIRE)--OQ Chemicals launches biomass-balanced OxBalance Neopentyl Glycol Diheptanoate for the cosmetic industry as alternative to cyclic silicones (D5).

OQ Chemicals Launches Biomass-Balanced OxBalance Neopentyl Glycol Diheptanoate for Cosmetics

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced that its Ambulnz subsidiary has launched emergency medical and 911 services in Dover, Delaware. On July 1, 2024, Ambulnz began providing basic life support (BLS) ambulances 24 hours a day, seven days a week, operating out of three stations in the Dover Fire District. The services are supported by a local management team and over 50 EMS.

Ambulnz by DocGo Launches Emergency Medical Services in Dover, Delaware

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Starts Probe Into DocGo Inc And Urges Affected Investors To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investigation Into DocGo Inc Initiated By The Schall Law Firm Encouraging Impacted Investors To Begin Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DocGo Inc Under Investigation By The Schall Law Firm Urging Affected Investors To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Inquiry Into DocGo Inc And Encourages Impacted Investors To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Starts Investigation Into DocGo Inc And Urges Affected Investors To Initiate Conversation

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced its partnership with Spect, a leading provider of comprehensive digital services for eye exam screenings, including diabetic retinopathy. Leveraging Spect's innovative hand-held retinal cameras, DocGo's mobile health clinicians now have a more scalable and cost-effective way to bring diabetic retinopathy and other eye disease screening.

DocGo and Spect Partner to Reduce Care Gaps and Improve Eye and Vision Health

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Probe Into DocGo Inc And Encourages Impacted Investors To Start Communication

LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Starts Scrutiny Of Allegations Against DocGo Inc And Promotes Investors With Losses To Initiate Communication

LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investigation Into DocGo Inc Is Launched By The Schall Law Firm And It Motivates Affected Investors To Commence Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Examination Into Accusations Against DocGo Inc And Encourages Impacted Investors To Start Interaction

LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Inquiry Into Allegations Against DocGo Inc And Urges Affected Investors To Initiate Communication

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Probe Into Claims Against DocGo Inc Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Contact

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Probe Into Claims Against DocGo Inc And Urges Impacted Investors To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Allegations Against DocGo Inc And Encourages Affected Investors To Establish Communication

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced it has secured five new contracts that include remote patient monitoring (RPM), virtual care management (VCM), chronic care management (CCM), cardiac implantable electronic device (CIED), and a care gap closure program for a national health plan. These noteworthy examples of new DocGo contracts expand the Company's reach and ability to.

DocGo Secures Five New Contracts to Provide Healthcare In Markets Across the United States

LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Probe Into Claims Against DocGo Inc And Urges Impacted Investors To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for DocGo Stock (DCGO)